Cure8 news brief
This signals new investigational IBD research focused on a novel immune pathway (TL1A/DR3) that could lead to future treatments. For people with Crohn’s/IBD, it’s an early-stage development to watch, but not an immediate treatment option.
Researchers and clinicians interested in IBD drug development, patients following new biologic therapies, and patient advocates tracking emerging therapeutic targets.
Shattuck Labs announced a poster presentation at the 2025 Crohn’s and Colitis Congress reporting preclinical/early-stage work on SL-325, described as a DR3-targeted antagonistic antibody aimed at treating IBD. The company says the poster will be presented on Feb 7, 2025, and materials will be posted on its website afterward.
The report appears to be an event/press announcement rather than published clinical trial results; it describes SL-325 as a ‘first‑in‑class’ DR3 antagonist targeting the TL1A/DR3 pathway and positions the work as development and characterization of the molecule. No clinical efficacy, safety data, or patient-level outcomes are provided in this announcement.
If you want details, check the company’s Events and Presentations page after the congress to view the poster or contact Shattuck Labs for the full materials. The poster presentation at the Crohn’s and Colitis Congress is the primary source of the information summarized here.
This is a company press announcement about a conference poster — not a peer‑reviewed paper or completed clinical trial. The poster may present preclinical or early translational data; wait for the poster itself or subsequent publications for detailed methods and results.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This is early-stage research about combining antibody targets (α4β7 and TL1A) for IBD; if validated in humans, combination biologics could offer improved effectiveness or dosing convenience.
TREMFYA (guselkumab) is an IL-23 inhibitor being studied for ulcerative colitis and Crohn's disease; new trial data could affect future treatment options. For people with IBD, drug-development news may indicate upcoming...
Fibrostenotic Crohn’s disease (intestinal strictures from scar tissue) has few non-surgical treatment options. An investigational drug aimed at fibrosis could eventually offer a medical alternative to surgery if research...
